KPV is a synthetic tripeptide corresponding to the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). Early research focused mainly on inflammatory-signaling pathways, while more recent studies have extended to keratinocyte responses, oxidative stress and environmental-stimulus models. The current evidence base remains dominated by cell and animal studies. This article summarizes why KPV is attracting research interest, what the evidence does and does not show, and what research buyers should verify when sourcing KPV peptide. It does not provide clinical-use or dosing recommendations.
What Is KPV Peptide?
KPV is a three-amino-acid peptide with the sequence Lys-Pro-Val, written as H-Lys-Pro-Val-OH in its free form. It corresponds to the C-terminal tripeptide (positions 11–13) of α-MSH, the 13-amino-acid melanocortin peptide. KPV corresponds to α-MSH(11–13), but it should not be treated as functionally equivalent to full-length α-MSH. Its activity, receptor dependence and experimental effects must be evaluated from KPV-specific evidence.
Why Is KPV Being Studied?
Research interest in KPV is spread across several experimental directions:
- Inflammatory-signaling studies
- Oxidative-stress-related models
- Keratinocyte responses
- Intestinal peptide transport (PepT1-mediated uptake)
- Experimental tissue-protection models
- Skin and keratinocyte stress models
These are research directions, not established clinical applications. Most of the published data come from cell-based and animal models.
What Is New in Skin-Stress Research?
A 2025 study published in Tissue & Cell examined KPV in human HaCaT keratinocytes exposed to PM10 fine particulate matter. Under the tested conditions, KPV was associated with reduced ROS production, modulation of ERK/p38 MAPK and NF-κB signaling, lower IL-1β secretion and changes in apoptosis-related markers. The researchers also evaluated KPV in a 3D skin model. These findings expand KPV research into environmental skin-stress models, but they do not establish clinical efficacy in humans.
The significance for KPV research is the addition of a directly skin-relevant environmental-stress model, extending the experimental evidence beyond classical inflammatory pathways into pollution-related keratinocyte stress.
The practical takeaway for 2026 is that KPV remains a research molecule. The interesting part of the current literature is the range of models being tested, not a confirmed therapeutic outcome.
How Does KPV Relate to α-MSH?
α-MSH is a longer endogenous peptide (13 amino acids) with multiple melanocortin-receptor-related functions. KPV corresponds to its C-terminal tripeptide, α-MSH(11–13). Published studies have examined the anti-inflammatory activity of the core and C-terminal peptides of α-MSH separately, and work in human keratinocyte cells has specifically addressed α-MSH, MSH 11-13 (KPV) and adrenocorticotropic hormone signaling.
Because KPV is a fragment, some experimental effects of full α-MSH cannot simply be assigned to KPV. Receptor dependence may also differ: KPV-related effects have been studied both through melanocortin receptors and through other transport or signaling routes depending on the model. The melanocortin receptor family is a normal reference point for α-MSH biology, but KPV research should be read on its own terms rather than assuming the same receptor profile as the full peptide.
What Does the Current Evidence Not Prove?
The available literature includes cell and animal studies, for example the PepT1-mediated intestinal inflammation model in which KPV uptake was examined. The cited preclinical evidence does not establish any of the following:
- Treatment of eczema
- Treatment of psoriasis
- Treatment or repair of intestinal disease
- A confirmed human dose-response relationship
- Long-term safety in humans
- Any basis for self-administration by consumers
Early-stage research should not be presented as a confirmed treatment outcome, and any commercial use of KPV must comply with the applicable regulatory framework in the target market.
Why Product Identity Matters
KPV is typically supplied as a research peptide, and the supplied form affects how it can be used:
- Free base versus acetate or other salt forms
- Peptide purity versus peptide content (assay)
- Water and counter-ion content
- HPLC retention time and chromatographic profile
- LC-MS molecular-weight confirmation
- Microbiological and endotoxin specifications, depending on the intended research use
A "99% purity" statement alone is not a sufficient quality basis. HPLC area purity and peptide content describe different attributes and should both be confirmed for research-grade sourcing.
Research-grade documentation differs from a cosmetic-grade summary in one important way: it should state what was measured, on which batch, and by which method. Buyers planning cell or animal work should ask whether the assay, counter-ion, water and endotoxin data refer to the exact supplied batch rather than to a representative specification.
What Should B2B Buyers Request?
For research sourcing of KPV peptide, buyers should request:
- Batch-specific COA
- HPLC chromatogram
- LC-MS report
- Sequence confirmation
- Peptide assay
- Water content
- Acetate/TFA content
- Residual-solvent information
- Storage conditions
- Intended-use statement
- Batch traceability
Documentation should match the exact supplied batch and form, not a generic specification sheet. The intended-use statement is particularly relevant for KPV: a research peptide supplied for laboratory use is a different regulatory situation from a material intended for consumer products, and the buyer should confirm which category the supply falls into.
2026 Research Outlook
Skin-environment-stress models represent an emerging direction in KPV research, while delivery, stability and dose-response questions still require further experimental work. Human evidence remains the key gap, and suppliers should avoid presenting early-stage research as confirmed therapeutic results. For buyers, the near-term value of KPV is as a research peptide with documented identity, assay and batch traceability - not as a finished-treatment claim. Sourcing decisions should therefore be driven by documentation quality and batch consistency, the same criteria that apply to any early-stage research peptide.
FAQ
What is KPV peptide?
KPV is a synthetic tripeptide with the sequence Lys-Pro-Val (H-Lys-Pro-Val-OH), corresponding to the C-terminal fragment of α-MSH.
Is KPV derived from α-MSH?
KPV corresponds to positions 11–13 (the C-terminal tripeptide) of α-MSH. It is a fragment, not the full peptide, and its effects should be evaluated separately.
Is KPV an approved drug?
No. KPV is a research peptide; published data are dominated by cell and animal models, and no human clinical indication is established.
Is KPV a cosmetic ingredient?
KPV is primarily discussed and supplied as a research peptide. Buyers considering any cosmetic application should verify the ingredient's current regulatory and inventory status in the specific target market before product development or commercialization.
What documents should research buyers request?
Batch-specific COA, HPLC chromatogram, LC-MS report, sequence confirmation, peptide assay, water and counter-ion content, residual-solvent data, storage conditions and batch traceability.
Looking for KPV peptide powder for laboratory research? HDM Biotech provides batch-specific COA, analytical documentation, sample support and bulk supply options according to the confirmed product specification.
Contact:
Whatsapp & Mobile: +86 19991242181
Email:sales@hdmbio.com
References
- Sung J, Ju S-Y, Park S, Jung W-K, Je J-Y, Lee S-J. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue & Cell. 2025;95:102837. DOI: 10.1016/j.tice.2025.102837. PMID: 40073467.
- Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631–637. PMID: 12750433.
- Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. Journal of Investigative Dermatology. 2004;122(4):1010–1019. PMID: 15102092.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID: 18061177.
- Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology. 2016;2(3):340–357. PMID: 27458604.